구조모아 (StructureMoa)항암 chemical structure spider web
방문3D Medicines (Sichuan) Co.Ltd.
Envafolimab(3D Medicines (Sichuan) Co., Ltd.)은 Prostate Cancer 표적 항체로, Prostate Cancer; CDK12 Gene Mutation 영역에서 개발·상용화 중입니다. 작용기전: of envafolimab (also known as KN035), a programmed death ligand 1 (PD-L1) inhibitor, in gastric adenocarcinoma patients with low PD-L1 expression is not well understood. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 52건의 관련 임상이 등록되어 있습니다. 차별점: novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Prostate Cancer
Prostate Cancer; CDK12 Gene Mutation
Recruiting
2026-07-12
Data Confidence · Low
Development Signal · Emerging
humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection
novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
of envafolimab (also known as KN035), a programmed death ligand 1 (PD-L1) inhibitor, in gastric adenocarcinoma patients with low PD-L1 expression is not well understood
T-cell activation
apoptosis of gastric cancer cells was detected by flow cytometry
PD-L1)-positive
Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra
구조화 데이터
mouse
PD
구조화 데이터
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
3D Medicines (Sichuan) Co.Ltd.
Envafolimab(3D Medicines (Sichuan) Co., Ltd.)은 Prostate Cancer 표적 항체로, Prostate Cancer; CDK12 Gene Mutation 영역에서 개발·상용화 중입니다. 작용기전: of envafolimab (also known as KN035), a programmed death ligand 1 (PD-L1) inhibitor, in gastric adenocarcinoma patients with low PD-L1 expression is not well understood. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 52건의 관련 임상이 등록되어 있습니다. 차별점: novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Prostate Cancer
Prostate Cancer; CDK12 Gene Mutation
Recruiting
2026-07-12
Data Confidence · Low
Development Signal · Emerging
humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection
novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
of envafolimab (also known as KN035), a programmed death ligand 1 (PD-L1) inhibitor, in gastric adenocarcinoma patients with low PD-L1 expression is not well understood
T-cell activation
apoptosis of gastric cancer cells was detected by flow cytometry
PD-L1)-positive
Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra
구조화 데이터
mouse
PD
구조화 데이터
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.